China biotech RiboX reveals first data of circular RNA therapies in people

Chinese biotech RiboX Therapeutics has become the first company to publish clinical data showing that a circular RNA therapy can work in people. The results appeared in the New England Journal of Medicine, one of the most closely watched medical journals in the world. They describe RXRG001, a circular RNA candidate that improved saliva production in patients with xerostomia, commonly known as dry mouth.

The publication puts RiboX ahead of better-known Western rivals, including Orna Therapeutics, Orbital Therapeutics, and Sail Biomedicines, all of which have raised substantial funding to develop circular RNA medicines. For a field that has so far lived mostly in preclinical studies and investor presentations, the data marks a notable shift. I should note that I am working only from the headline and summary you gave me, so the specific figures and trial Details are not covered here.

Why This Circular RNA Milestone matters Now

Circular RNA is a form of RNA whose ends are joined into a closed loop. Unlike linear messenger RNA, it has no free ends for cellular enzymes to attack, which can make it more stable. In theory, that stability could allow longer-lasting protein production from smaller or less frequent doses.

Until now, that promise was backed mainly by animal studies and laboratory work. Human data was the missing piece, and many researchers wanted to know whether the loop structure would behave safely and effectively in patients. RiboX's publication is the first public answer to that question.

What RiboX Reported About RXRG001 in Patients

According to the report, RXRG001 improved saliva flow in patients with xerostomia. Xerostomia is a condition often linked to radiation therapy for head and neck cancers and to autoimmune diseases such as Sjögren's syndrome. It can seriously affect eating, speaking, sleeping, and dental health.

Publication in NEJM suggests the early results passed demanding peer review. Even so, first-in-human studies are usually small and designed mainly to assess safety and look for early signals. Readers should treat the findings as an encouraging start, not proof of long-term benefit.

The Unmet Need Behind Dry Mouth Treatment

Current options for xerostomia are limited. Patients often rely on saliva substitutes, frequent sipping of water, or drugs that stimulate saliva glands but cause side effects and do not work for everyone. Those whose glands are badly damaged by radiation often have very few choices.

A therapy that prompts the body to restore its own saliva function would address a real gap. That is one reason a localized therapy for a salivary gland condition may be a sensible first test of a new RNA format. A targeted setting can limit exposure while still showing whether the molecule does its job.

How RiboX Got Ahead of Western Competitors

Orna, Orbital, and Sail Biomedicines have each attracted major attention and capital as circular RNA specialists. Their programs have largely been described in terms of platform potential and preclinical progress. RiboX, by contrast, now has human results in a leading journal.

The development also reflects the growing strength of Chinese biotech in cutting-edge modalities. Companies in China have increasingly moved quickly into early clinical testing, sometimes running first-in-human studies faster than peers elsewhere. That speed can translate into a lead in emerging fields.

What Circular RNA Could Mean for Medicine

If circular RNA proves reliable in the clinic, it could broaden what RNA medicines can do. Greater stability may allow durable expression of therapeutic proteins, which could help in diseases where mRNA's short duration has been a limitation. Potential applications range from protein replacement to vaccines and immune-related therapies.

Manufacturing and delivery remain open questions. Producing pure circular RNA at scale and getting it into the right cells are technical hurdles that every company in the space must solve. The first human data does not settle those issues, but it shows that the approach is feasible.

Caveats and Questions Still Facing the Field

Early clinical data comes with limits. Small patient numbers, short follow-up, and the lack of large control groups mean it is too soon to judge how durable or broadly useful RXRG001 will be. Safety over longer periods, including immune responses to repeated dosing, will also need careful study.

Independent confirmation will matter too. Larger and more rigorous trials will have to show that saliva improvements translate into meaningful gains in symptoms and quality of life. Regulators will want to see consistent results before considering any approval.

What to Watch From RiboX and Its Rivals

The next steps for RiboX will likely include larger studies and possibly expanded indications. Investors and partners will watch closely for signs that the company can turn a first-in-human success into a full development program. Any collaboration or financing news could follow quickly after such a high-profile publication.

Meanwhile, Orna, Orbital, and Sail Biomedicines will face pressure to show their own clinical results. The competition is likely to accelerate progress across the field. For patients and researchers, the race to bring circular RNA into real-world treatment has now truly begun.

If you have any questions, please don't hesitate to Contact Us